Applying integrated and efficient translational science to develop new treatments that help combat and cure diseases.
Bringing transformational treatments to patients sooner
【公司簡介】尚未提供英文翻譯內容
Our Pipeline
Our extensive experience and unique drug development engine enable us to identify and incubate high-potential novel drug candidates and rapidly deliver partner-ready clinical assets. Our lead platform is our proprietary Pigment Epithelium-Derived Factor (PEDF) derived Short Peptide (PDSP), which can be applied across multiple therapy areas and indications. PDSP is a multifunctional secreted protein that has anti-angiogenic, anti-tumorigenic, and neurotrophic functions. This platform opens up exciting possibilities for wound healing and tissue regeneration due to its ability to enhance cell proliferation and differentiation.
Worldwide license for developing PDSP
In 2015, BRIM was granted an exclusive, worldwide license for developing PDSP in all therapeutic indications including dry eye disease, corneal wound healing, diabetic ulcer wound healing, osteoarthritis, androgenic alopecia, and muscle/tendon regeneration.
Our lead assets
Our lead asset, BRM421, is on track to become a first-in-class treatment for dry eye disease (DED) which treats and repairs cornea damage. BRM421 has demonstrated safety and efficacy in two clinical studies. BRIM is devoted to expanding this synthetic peptide’s indications, including treatments for neurotrophic keratitis (BRM424), and osteoarthritis (BRM521).
Award
2020Taipei Biotech Awards
Innovative Technology Award – Gold Prize
2020Taiwan BIO Awards
Outstanding Company of the Year
2019National Innovation Award
National Innovation Award
2019Prominent Enterprise Awards
Outstanding Fundraising Award
More
